AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences, Inc. (AURA) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+). The rating has held at C for 11 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D+ (1.8) | C+ (2.6) | C (2.4) | C+ (2.6) | C (2.4) |
| 2026-11-10 | C+ (2.5) | C- (1.9) | C+ (2.6) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-11-03 | C+ (2.5) | D+ (1.8) | C+ (2.6) | C (2.2) | C+ (2.7) | C (2.4) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | C+ (2.6) | C (2.3) | C+ (2.6) | C (2.4) |
| 2026-10-20 | C+ (2.5) | D+ (1.8) | C+ (2.6) | C (2.4) | C+ (2.6) | C (2.4) |